



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

August 13, 2025

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
Scrip Code: 543434

National Stock Exchange of India Limited  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (E), Mumbai - 400 051  
NSE Symbol: SUPRIYA

Dear Sir/Madam,

**Subject: Investor Presentation.**

Further to our Letter dated August 7, 2025, we are enclosing herewith Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended on June 30, 2025.

Kindly take the information on record.

Thanking you,

**For Supriya Lifescience Limited**

**Prachi Sathe**  
**Company Secretary & Compliance Officer**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA  
LIFESCIENCE LTD.**



# **SUPRIYA LIFESCIENCE LTD.**

**Investor Presentation | Q1 FY26**

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Supriya Lifescience Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.






## **Q1 FY26 Highlights**




**SUPRIYA  
LIFESCIENCE LTD.**

Quarterly




Regional Performance




# Q1 FY26 - Y-o-Y Highlights

(in INR Mn)



## Performance of the Top Therapeutic Areas



# Profit & Loss Statement



SUPRIYA  
LIFESCIENCE LTD.

Particulars (in INR Mn)	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	Q-o-Q
<b>Revenue from Operations</b>	<b>1,450.7</b>	<b>1,606.3</b>	<b>-9.7%</b>	<b>1,841.1</b>	<b>-21.2%</b>
Cost of Goods Sold	317.72	486.0	-34.6%	548.3	-42.0%
Employee Benefits Expense	226.9	200.8	13.0%	209.8	8.2%
Other Expenses	389.1	294.0	32.3%	407.2	-4.4%
<b>EBITDA</b>	<b>517.0</b>	<b>625.4</b>	<b>-17.3%</b>	<b>675.8</b>	<b>-23.5%</b>
<b>EBITDA %</b>	<b>35.6%</b>	<b>38.9%</b>	<b>-330 bps</b>	<b>36.7%</b>	<b>-107 bps</b>
Other Income	26.7	22.2	20.2%	29.7	-10.1%
Depreciation and Amortisation Expense	64.5	46.6	38.5%	60.8	6.1%
<b>EBIT</b>	<b>479.2</b>	<b>601.1</b>	<b>-20.3%</b>	<b>644.8</b>	<b>-25.7%</b>
Finance Costs	5.1	3.4	52.7%	4.2	22.5%
<b>PBT</b>	<b>474.1</b>	<b>597.7</b>	<b>-20.7%</b>	<b>640.6</b>	<b>-26.0%</b>
Total Tax Expense	126.2	151.3	-17.1%	136.8	-8.3%
<b>Profit for the year</b>	<b>347.9</b>	<b>446.4</b>	<b>-21.9%</b>	<b>503.8</b>	<b>-30.8%</b>
<b>PAT %</b>	<b>24.0%</b>	<b>27.8%</b>	<b>-376 bps</b>	<b>27.0%</b>	<b>-333 bps</b>
<b>EPS (INR)</b>	<b>4.3</b>	<b>5.5</b>		<b>6.3</b>	





## **Company Overview**



**SUPRIYA  
LIFESCIENCE LTD.**

Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthmatics & Anesthetics

<p><b>40+</b> APIs</p> <p>Niche product basket</p>	<p><b>120+</b> Countries</p> <p>Diversified operations with presence</p>	<p><b>33,000</b> Sq.mts</p> <p>Manufacturing facility spread across</p>	<p><b>932</b> KLPD</p> <p>Reactor capacity</p>
<p>WHO-GMP, Written Confirmation, ISO, Halal, Indonesian Halal. Fami QS</p>	<p><b>40+</b></p> <p>Years of excellence in manufacturing</p>	<p><b>85%</b></p> <p>Revenue from exports</p>	<p><b>1,500+</b></p> <p>customers</p>



3 Times approved



2 times approved



# Journey So Far



SUPRIYA  
LIFESCIENCE LTD.

2020

Third time  
USFDA approval

2021

CEP granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate; NMPA approval granted; Health Canada approval

Listed on Stock Exchange  
BSE & NSE

2022

CEP (Certificate of suitability ) renewed for Pheniramine Maleate, Chlorpheniramine Maleate and Ketamine Hydrochloride

2023

The Company commenced operations at its new R&D lab in Lote Parshuram

2024

ANVISA Approval  
Granted

2018

CEP granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride

2017

CEP granted for Pheniramine Maleate; Second time USFDA approval granted

2015

EUGMP and EDQM approval granted

2014

USFDA approval granted; IDL granted for Brompheniramine Maleate

2013

COFEPRIS and KFDA approval granted



2008

Incorporation & conversion from a partnership firm to a public limited company

2009

Started production of Ketamine hydrochloride


2010

CEP granted for Chlorphenamine Maleate

2011

IDL granted for Chlorphenamine Maleate

# Backward Integrated Business Model



## 18 products are backward integrated\* in following therapies


Anesthetics	Anti-Asthmatic	Anti-Histamine
Decongestant	Anti-Gout	

*Note: In the process of further backward integrating 3 more products*

**81%**  
of Q1 FY26 revenue

Integrated business model helped us grow revenue and sustain margins in the last year. Large part of growth and sustainability was driven by these backward integrated products





## Launches

### New Therapies

- Contrast Media
- Cardio Vascular
- ADHD


### New Products

Launched new product to further strengthen the Anesthetic therapy portfolio

# Diversified Revenues with Extensive Global Presence


## Significant export presence, with low dependence on a specific geography

Export sales, as a % of revenue from operations



## ... with balanced customer concentration

Share of top 10 customers, as a % of revenue from operations



## Long standing relationship with global pharma companies ...



## ... We plan to further reduce customer concentration

Penetration of existing products to newer geographies by registering these products

Adding new niche products with high volume potential for which we are building 2 new R&D centers

CMO/CDMO opportunities




- Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, warehouse, raw materials, packaging materials and finished goods stores
- Recently commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
- Commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
- Strategic Land Acquisitions:**
  - **12,551 sq.mt.:** Adjacent to the existing facility to enable seamless future growth and expansion
  - **24,646 sq.mt.:** Located 20 km from the current facility, strategically acquired for backward integration to enhance operational efficiency
  - **80,000 sq.mt.:** Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.



**5**

**Manufacturing Blocks**



**9**

**Clean Rooms**



**932 KLPD**

**Reactor Capacity**



**33,000sq.mt.**


**Land Area**

## Scaled up Manufacturing Facilities over the years

	Block A	Block B	Block C	Block D	Block E
Year of Establishment	1993	1994	2014	2021	2024
Capacities	157 KLPD	195 KLPD	30 KLPD	215 KLPD	335 KLPD
Regulatory Approved	✓	✓	✓	✓	✓

## Healthy capacity utilization

Ramp up of production from Module E will drive the capacity utilisation



4\*

Process Patent  
Filed in India

## Supported by R&D driven mindset

- A team of 60+ scientists primarily focused on API process development across the value chain
- Already started two R&D centres –
  - Ambernath R&D – for formulations and
  - Lote R&D – Generic APIs & Lifecycle improvement
- Consistent efforts to develop new products, improve existing formulations, enhance drug delivery systems, and expand product applications
- Ongoing efforts to add 3-4 products every year






- State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
- Complete support in validation, stability, & compilation of dossiers
- Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
- Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions
- Recently added Kilolab to strengthen capabilities in high-value small-molecule APIs





# Recently Commissioned state-of-the-art E Block

- Capacity: **335 KLPD**
- Large volume equipment – multipurpose synthesis with focus on backward integration capabilities
- Closed systems using gravity flow equipped with process control system.



# FDF Facility ready for commissioning at Ambernath



## Facility Location

- The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Additional Ambernath MIDC, District Thane, Maharashtra,
- Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.



## R&D

- Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms
- Analytical laboratories & Complex API synthesis facilities alongside dosage forms development for efficiency
- Focus areas – complex forms, anti-diabetics, anesthetics.



## Manufacturing

- FDF facilities to commission from H2 FY26
- Tablets, capsules and liquids
- Large volume liquids filling line
- Validation and registration batches for dossier submissions.



Focus on uniform manufacturing standards to achieve standardised product quality across markets

## Ability to handle complex chemistries..

- Simple to highly complex chiral molecules
- Controlled substances
- Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
- Precision distillation of volatile inhaled Anesthetic APIs yielding high purity > 99.97%.

... across varied class of reactions

Cyclisation      High vacuum distillations

Grignard reaction

Fridel craft acylation

Decyanation      Etherification

Formylation      High pressure catalytic reductions

Bromination      Nitration

Oxirane      Lithiation



Focus on uniform manufacturing standards to achieve standardised product quality across markets

## Ability to handle complex chemistries..

- Contrast media API synthesis
- Use of Resin for purification
- Novel amide formation techniques using low price reagents
- Handling of highly moisture sensitive API and intermediates

... across varied class of reactions

Chiral molecules synthesis using Chiral auxiliary

Amidation via Mixed anhydride

**Reductive amination**

Chlorination Contrast media API

Distillation for purification

Asymmetric catalytic reduction

Resin chemistry for purification

Resolution

Thermal cyclization **Debenzylation**

## Strong focus on compliance guided by ethical approach

- Our motto is to consistently meet the stringent requirements of regulatory bodies
- Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.

**50+**

Registrations in  
different countries



**19**

USDMF's



**10**

CADIFA Brazil



**3**

NMPA China



**500+**

Customer  
Audit Approvals



**10**

CEPs



**5**

KDMF Korea



**50+**

ROW



## 2016



- Export House for the Year for 2015-16 awarded by Directorate of
- Industries, Government of Maharashtra
- Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra

## 2017



- Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
- Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra

## 2019



- Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India
- 'Bharatiya Mahanatham Vikas Puraskar' for the year 2018-19 from Asia One Magazine.
- 'Outstanding Export Performance Award' for the year 2018-19 from Pharmaceuticals Export Promotion Council of India.

## 2025



- PMA Eminence Award 2025 in category Exporter of the Year from Pune Management Association on 27th May 2025 at Auto Cluster Auditorium, Pune.
- "The Diamond Jubilee All India Export Excellence Awards" by Federation of Industries of India on 27th May 2025 at Federation House, Thane.




# Key Management Team



## Satish Wagh

### Executive Chairman & WTD

- An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University.
- B.Sc. from R.D National College and W.A. Science College, University of Bombay.
- Director on the board of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.



## Saloni Wagh

### Managing Director

- Ph.D. in chemistry from the Faculty of Science, Pacific University, Udaipur.
- M.Sc. from Institute of Science, University of Mumbai.
- B.Sc. from Parle Tilak Vidhyalaya Association's Sathaye College, University of Mumbai.



## Shivani Wagh

### Joint Managing Director

- Master's degree in International business management from Manchester Business School, University of Manchester.
- Bachelor's degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai.



## Krishna Raghunathan

### Chief Financial Officer

- Chartered Accountant (CA) from ICAI
- Bachelor degree of Science in Zoology from Madras University.
- Previously associated with companies like Dr. Reddy's Laboratories Limited and Granules India Limited.



## Environment

- Regular and strict monitoring to produce highest efficiency in pollution control
- Commitment to reduce, recycle and reuse all resources for conservation and waste reduction, wherever feasible
- Own ETP facility – 400 KLPD, 2000 KL retention volume
- CETP membership – additional discharge of 260 KLPD
- Over the years about 56% reduction in cost reduction and relevant oil consumption
- Focus on solvent recovery, reduced emissions
- Adoption of paperless culture since 2015
- Implementation of ERP system has drastically reduced use of overall paper.



## Health

- Clean, safe and healthy working environment for our all employees
- Mandatory medical examination and periodic medical checkup
- Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.



## Safety

- Committed to safe and accident-free operations in all our establishments
- Safeguarding our employees and facilities by acquiring the knowledge of hazardous industrial activities carried out in the neighborhood
- Frequent fire safety mock drills and intensive training programs to inculcate safety awareness and adherence to safety policies
- Periodic internal and external audit for ensuring compliance to our safety policy.
- Implementation of closed-system pneumatic transfer systems for material handling, replacement of liquid bromine with safer alternatives, establishment of a robust work permit system, and deployment of process control systems to monitor safety-critical parameters.



**We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm**

- Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
- Supporting and participating with NGOs in chosen fields
- Utilization of CSR funding for drinking water scarcity in villages near our factory site
- Contribution to Prime Minister National Relief Fund
- Support patients for cancer treatment
- Fund raisers and donations to worthy social causes, etc.








## Historical Financial Performance




**SUPRIYA  
LIFESCIENCE LTD.**

# Consistent & Strong Financial Performance


## Robust revenue growth




## Capex Spend




## ... and, focus on profitability



## Return on Net Worth




## Healthy leverage profile




# Working Capital Break-up


## Inventory




## Receivables



## Payables



## Net Working Capital





## **Future Outlook**



**SUPRIYA  
LIFESCIENCE LTD.**



## Two new R&D centres

- The future of the company is deeply rooted in R&D, with significant progress made to enhance research capabilities
  1. The R&D lab at Lote Parshuram spans **800 sqm** and is equipped with **20 fume hoods**. This facility focuses on lifecycle management, backward integration, new product development, and CMO/CDMO opportunities
  2. The Ambarnath R&D lab is now fully operational, supporting the next phase of the company's expansion and innovation strategy.
- These centres will help to develop identified APIs which will complement existing product profile
- The controlled drugs portfolio is set to be expanded, with potential APIs already identified and currently in the development pipeline. Additionally, the company is evaluating product portfolio expansion by selecting new products in the anti-diabetic and anesthetic segments.



## New markets

- Company is currently doing business with over **1500+** customers and has presence in more than **120+** countries
- The geographical locations are distributed within sales team to focus on sustaining the business and expansion through new customer acquisition
- For regulated market, regulatory team is registering the products and filling DMFs. Sales team is in discussion with new customers to qualify us as a reliable source and started sending samples and supplying APIs for their product validation
- Company has taken additional steps for business expansion around the globe especially in North America, Japan, Australia and New Zealand.



## CMO/CDMO space

- Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry
- Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products as per their needs
- We have recently announced one of our key CMO project with a leading European company where we will be exclusive API supplier. The contract spans a period of 10 years and is expected to generate peak revenue of **INR 60 crs/year** starting from FY27
- In addition to the aforementioned contract, the company has identified two similar opportunities in the API and advanced intermediate space, along with several other potential opportunities.



## Capacity enhancement

- **Commissioned State-of-the-Art Module E Production Block at Lote Parshuram, boosting our capacity by over 55%, increasing it from 597 KLPD to 932 KLPD**
- Capacity enhancement for further backward integration of existing products, new product rollouts and CMO/CDMO opportunities
- We are developing a new formulation facility in Ambarnath, along with an R&D facility dedicated to the development of innovative products.





**SUPRIYA  
LIFESCIENCE LTD.**

**Supriya Lifescience Limited**

CIN: L51900MH2008PLC180452

Mr. Krishna Raghunathan - Chief Financial Officer

cfo@supriyalifescience.com

www.supriyalifescience.com



**Ernst & Young LLP**

**Runjhun Jain**

+91 98207 20993

runjhun.jain1@in.ey.com

**Sneha Salian**

+91 98194 30437

sneha2.salian@in.ey.com



**THANK YOU**